ClinicalTrials.gg
Not yet recruitingNCT07459829Updated Oct 23, 2026

Study of CU06-1004 in Patients With Daibetic Macular Edema

A Phase 2 interventional study of CU06-1004 and Placebo Control in DME, Diabetic Macular Edema and Diabetic Macular Edema (DME), sponsored by Curacle Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Curacle Co., Ltd. · Phase 2, Interventional, and Treatment

Updated Oct 23, 2026Primary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This phase 2b trial is a randomized, double-masked, parallel-group, multi-center study in approximately 156 patients with Diabetic Macular Edema to evaluate the efficacy and safety of CU06-1004 orally administered once daily for 24 weeks. The study will have a 1:1:1 randomization (CU06-1004 200mg: CU06-1004 300mg: Placebo).

02

Conditions studied

  • DME
  • Diabetic Macular Edema
  • Diabetic Macular Edema (DME)

Browse trials for

Keywords

  • Diabetic Macular Edema
  • DME
  • endothelial dysfunction blocker
03

In context

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

This study's planned enrollment of 156 is above the median of 56 across 586 interventional studies indexed under Macular Edema.

Browse Macular Edema studies →

Lead sponsor

Curacle Co., Ltd. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients will be eligible for inclusion in the study if they meet all of the following criteria:

  1. Have read, understood, and signed the form.
  2. Patient is willing and able to comply with all study procedures, and is likely to complete the study, based on the investigator's judgment.
  3. Male and female patients must be ≥18 years of age at the time of screening visit. Race and ethnicity information will be collected based on National Institutes of Health criteria.
  4. Has a diagnosis of Type 1 or Type 2 diabetes mellitus.
  5. Has definite retinal thickening due to DME in the center of the macula of the study eye (either treatment-naïve or previously treated patients).
  6. The study eye has a BCVA of 25 to 69 (approximate Snellen equivalent of 20/50 to 20/320) at an initial distance of 4 meters, as assessed by the ETDRS letter score at screening.
  7. Has a study eye with CST of ≥320 µm for men or ≥305 µm for women as determined by Heidelberg Spectralis (or equivalent) SD-OCT (or Zeiss Cirrus OCT: 305 µm for men or 290 µm for women) and confirmed by the CRC at screening.
  8. Has a DRSS score of ≥43 confirmed by the CRC.
  9. Has media clarity, pupillary dilation, and patient cooperation sufficient for adequate fundus photographs.
  10. Is willing to abide by the requirements.

Exclusion criteria

Exclusion Criteria:

Patients will be excluded from the study if they meet any of the following criteria:

  1. Has only 1 functional eye, even if the eye met all other study requirements, or has and/or is likely to have amblyopia, amaurosis, or an ocular disorder with BCVA ≤25 ETDRS letter score (approximate Snellen equivalent of \<20/320) in the fellow eye.
  2. Concurrent and/or history (where indicated) of an ocular condition including one or more of the following in the study eye:

    1. Active proliferative diabetic retinopathy (PDR) or preretinal fibrosis involving the macula.

      Note: Patients with mild PDR without high-risk features will be allowed in the study.

    2. Vitreomacular traction or epiretinal membrane that is expected to affect central vision.
    3. Iris neovascularization, vitreous hemorrhage, or tractional retinal detachment.
    4. Uncontrolled glaucoma or filtration surgery for glaucoma in the past or likely to be needed in the future
    5. Intraocular pressure (IOP) >24 mmHg at screening and randomization. IOP will be assessed by applanation tonometry (Goldmann tonometer, Tono-pen™, or an equivalent device).
    6. Spherical equivalent of the refractive error of more than 6 diopters myopia or any signs of myopic chorioretinopathy.
    7. Structural damage to the center of the macula that is likely to preclude improvement in BCVA following the resolution of macular edema, including atrophy of the RPE, subretinal fibrosis or scar, significant macular ischemia, or organized hard exudates.
    8. Disease other than DME, that could compromise visual acuity, require medical or surgical intervention during the study period, or could confound interpretation of the results (including retinal vascular occlusion, retinal detachment, macular hole, or choroidal neovascularization of any cause) as assessed by the investigator.
    9. Macular edema is of nondiabetic retinopathy etiology (eg, secondary to vitreomacular interface abnormalities).
    10. Inability to obtain fundus and OCT images due to, but not limited to, insufficient media clarity or inadequate pupil dilation.
    11. Aphakia or absence of the posterior capsule. Absence of an intact posterior capsule is allowed if it occurred because of Yttrium-aluminum-garnet (YAG) laser posterior capsulotomy in association with prior posterior chamber intraocular lens implantation longer than 2 months before screening.
  3. Concurrent and/or history (where indicated) of ocular condition including one or more of the following in either eye:

    1. There is evidence of external ocular infection, including conjunctivitis, chalazion, or significant blepharitis. However, a patient who has completely recovered from the infection at Week 1 (baseline) is allowed to be enrolled in the study at the investigator's discretion.
    2. Has any active intraocular inflammatory disease such as uveitis or a history of intraocular inflammatory disease other than what would be expected in the normal postoperative course following prior routine ocular surgery such as cataract surgery.
  4. Had major surgery within 3 months prior to randomization or has major surgery planned during the next 6 months.
  5. Had unstable angina, myocardial infarction, , cerebral infarction, coronary artery bypass surgery, or transluminal coronary angioplasty within 6 months before screening.
  6. Has the following illness or abnormal laboratory test values:

    1. Persisting elevations of or alanine aminotransferase >2 × (ULN)
    2. Uncontrolled hypertension (systolic blood pressure of >180 mmHg or diastolic blood pressure of >100 mmHg).
    3. Uncontrolled diabetes ( >12.0%).
    4. Total >1.5× upper limit of normal.
    5. Positive results for or or C viruses.
    6. Other abnormal laboratory values per the investigator's judgment.
  7. Has severe renal impairment, defined as an estimated ≤ 30 mL/min/1.73 m².
  8. Has an ocular condition (other than diabetes) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (eg, vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass Syndrome, foveal atrophy, pigmentary changes, dense subfoveal hard exudates, or a nonretinal condition).
  9. Is expected to have no improvement of decreased visual acuity in the opinion of the investigator, even if macular edema is resolved (eg, foveal atrophy, abnormal pigmentation, dense subfoveal hard exudate).
  10. Have administered vaccinium myrtillus extract or calcium dobesilate within 2 weeks before randomization.
  11. Have a to any of the product or similar class of drug and ingredient.
  12. A pregnant woman, lactating woman, or a female or male patient of who does not accept appropriate measures for at least 6 months prior to the first dose of the study treatment (hormonal contraceptives, intrauterine contraceptive device, sterilization of spouse [eg, vasectomy, tubal ligation], double-barrier method [eg, combinational use of spermicides and condoms, diaphragm, contraceptive sponge, or FemCap], sexual abstinence).
  13. Has a medical condition that, in the opinion of the investigator, would preclude participation in the study (eg, unstable medical status including blood pressure, cardiovascular disease, and glycemic control or a significant medical condition including end-stage renal disease and severe liver diseases).

    Patients with a study eye that meets any of the following criteria may not participate in this study:

  14. Has history of intravitreal (IVT) treatment with anti-VEGF agents prior to randomization: A 3-month washout for ranibizumab and bevacizumab, and a 4-month washout for aflibercept 2mg, (and 6 months for longer-acting agents such as faricimab or aflibercept 8mg) are required. Any patients with a history of prior brolucizumab use in the study eye will be excluded from this study.
  15. Has history of treatment with IVT or periocular triamcinolone acetonide or IVT dexamethasone within 12 months of screening or has received an IVT dexamethasone implant (Ozurdex), or fluocinolone acetonide implant (Iluvien) or Susvimo (ranibizumab) implant any time prior to randomization.
  16. Has history of panretinal scatter photocoagulation (PRP) or is anticipated to require PRP in the 3 months following randomization.
  17. Has history of focal laser treatment (focal/grid laser photocoagulation) within 3 months prior to randomization and/or focal laser scar in the fovea that could limit BCVA improvement in the study eye.
  18. Has history of ocular surgery (including cataract extraction, any intraocular surgery, etc) within 3 months prior to screening or anticipated within the next 6 months following randomization.
  19. Has history of retinal detachment or retinal detachment repair surgery.
  20. Has history of vitrectomy.
  21. Participation in another interventional clinical trial for DME in either eye within 90 days before screening or any previous participation in a clinical trial of systemic antiangiogenic drugs with receipt of a previous study drug within 180 days before screening or 5 times the half-life of the study drug used, whichever is longer.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    CU06-1004 200mg

    Oral dose of 200 mg CU06-1004 QD (two 100 mg capsules and one placebo capsule)

    Drug: CU06-1004

  • Experimental
    CU06-1004 300mg

    Oral dose of 300 mg CU06-1004 QD (three 100 mg capsules)

    Drug: CU06-1004

  • Experimental
    Placebo

    Oral dose of matching placebo QD (three placebo capsules)

    Drug: Placebo Control

Interventions

  • CU06-1004 is an oral capsule. At room temperature, it appears as a white to off-white powder. The 100 mg soft gelatin capsules contain a solution-based fill.

    Also known as: SAC-1004, CU06, CU06-RE, Riverstat

  • DrugPlacebo Control

    A matching placebo capsule administered orally

06

What researchers measure

Primary outcomes

  1. Change of best corrected visual acuity (BCVA)

    Mean change in best corrected visual acuity (BCVA) from baseline as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letters score at Week 24 in the study eye.

    Time frame: 24 weeks

Secondary outcomes

  1. Mean change in best corrected visual acuity (BCVA)

    Mean change in best corrected visual acuity (BCVA) from baseline as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letters score at Weeks 4, 8, 12, and 18.

    Time frame: Week 4,8,12 and 18

  2. Improvement or worsening rate of Early Treatment Diabetic Retinopathy Study (ETDRS) best corrected visual acuity (BCVA)

    Improvement or worsening rate of Early Treatment Diabetic Retinopathy Study (ETDRS) best corrected visual acuity (BCVA)from baseline: percentage of patients who gained/lost ≥5/10/15 letter score increase of vision in the ETDRS letter score from baseline at each visit.

    Time frame: Week 4, 8, 12, 18, 24, and 28

  3. Change in central subfield thickness (CST)

    Change in central subfield thickness (CST) in the study eye assessed at each visit by spectral domain optical coherence tomography (SD-OCT) measured by the central reading center (CRC) from baseline

    Time frame: Week 4, 8, 12, 18, 24, and 28

  4. Change in all other subfield thickness

    Change in all other subfield thickness (nasal, temporal, superior, and inferior) in the study eye from baseline, assessed at each visit by SD-OCT using the ETDRS macular grid (the area between 1 mm to 3 mm and 3 mm to 6 mm by quadrant).

    Time frame: Week 4, 8, 12, 18, 24, and 28

  5. Mean change in vessel density (VD) in the superficial capillary plexus (SCP)

    Mean change in vessel density (VD) in the superficial capillary plexus (SCP) measured by optical coherence tomography angiography (OCT-A) at Weeks 12 and 24 compared to baseline.

    Time frame: Week 12 and 24

  6. Change in ETDRS

    Change in ETDRS diabetic retinopathy severity scale (DRSS) at Weeks 12 and 24 as measured by the CRC compared to baseline.

    Time frame: Week 12 and 24

  7. Change in inner retinal thickness

    Change in inner retinal thickness (internal limiting membrane to other inner nuclear layer) as measured by SD-OCT segmentation and the CRC

    Time frame: Week 4, 8, 12, 18, 24, and 28

  8. Change in ganglion cell layer/inner plexiform layer volume

    Change in ganglion cell layer/inner plexiform layer volume by OCT macular cube segmentation as measured by the CRC at Weeks 12 and 24 compared to baseline.

    Time frame: Week 12 and 24

  9. Change in fluorescein angiography leakage area

    Change in fluorescein angiography leakage area at Weeks 12 and 24 compared to baseline as measured by the CRC.

    Time frame: Week 12 and 24

  10. Change in choroidal vessel density/area and foveal avascular zone size

    Change in choroidal vessel density/area and foveal avascular zone size measured by OCT-A (and CRC) at Weeks 12 and 24 compared to baseline.

    Time frame: Week 12 and 24

  11. Percent of patients requiring rescue treatment

    Time frame: Week 4, 8, 12, 18, 24, and 28

  12. Change in blood biomarkers

    (TNF-alpha, MMP-9, Ang-2, HbA1c, Cystatin-C, vWF, and sTM)

    Time frame: Week 12 and 24

  13. Percent change in urinary albumin-to-creatinine ratio and eGFR

    Time frame: Week 24

  14. Mean change in vascular perfusion (VP) in the superficial capillary plexus (SCP)

    Mean change in vascular perfusion (VP) in the superficial capillary plexus (SCP) measured by optical coherence tomography angiography (OCT-A) at Weeks 12 and 24 compared to baseline.

    Time frame: Week 12 and 24

  15. Mean change in vascular perfusion (VP) in the deep capillary plexus (DCP)

    Mean change in vascular perfusion (VP) in the deep capillary plexus (DCP)measured by optical coherence tomography angiography (OCT-A) at Weeks 12 and 24 compared to baseline.

    Time frame: Week 12 and 24

  16. Mean change in vascular perfusion (VP) in the peripapillary capillary plexus (PCP)

    Mean change in vascular perfusion (VP) in the peripapillary capillary plexus (PCP) measured by optical coherence tomography angiography (OCT-A) at Weeks 12 and 24 compared to baseline.

    Time frame: Week 12 and 24

Other outcomes

  1. Mean change in BCVA

    Mean change in BCVA from baseline as measured by ETDRS letters score at each postbaseline visit. - fellow eye

    Time frame: Week 4, 8, 12, 18, 24, and 28

  2. Improvement or worsening rate of ETDRS BCVA

    Improvement or worsening rate of ETDRS BCVA from baseline: percentage of patients who gained/lost ≥5/10/15 letter score increase of vision in the ETDRS letter score from baseline - fellow eye

    Time frame: Week 4, 8, 12, 18, 24, and 28

  3. Change in CST

    Change in CST assessed at each visit by SD-OCT measured by CRC from baseline.

    Time frame: Week 4, 8, 12, 18, 24, and 28

  4. Change in ETDRS DRSS

    Change in ETDRS DRSS at Weeks 12 and 24 measured by CRC compared to baseline. - fellow eye

    Time frame: Week 12 and 24

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jan 2028, 13 months later.

Of 32 industry-sponsored phase 2 interventional studies under Macular Edema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's planned 13 months is below that.

Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 15 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 10, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Jan 1, 2028
CompletionEst.
Jan 30, 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange of best corrected visual acuity (BCVA)Time frame: 24 weeks
Oct 23, 2026
Secondary outcomes
3 edited
What changed in the outcomes
  • EditedMean change in best corrected visual acuity (BCVA)Time frame: Week 4,8,12 and 18
  • EditedImprovement or worsening rate of Early Treatment Diabetic Retinopathy Study (ETDRS ) best corrected visual acuity (BCVA)Time frame: Week 4, 8, 12, 18, 24, and 28
  • EditedChange in central subfield thickness (CST)Time frame: Week 4, 8, 12, 18, 24, and 28
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange of best corrected visual acuity (BCVA)Time frame: 24 weeks
    Secondary outcomes 3 edited
    What changed in the outcomes
    • EditedMean change in best corrected visual acuity (BCVA)Time frame: Week 4,8,12 and 18
    • EditedImprovement or worsening rate of Early Treatment Diabetic Retinopathy Study (ETDRS ) best corrected visual acuity (BCVA)Time frame: Week 4, 8, 12, 18, 24, and 28
    • EditedChange in central subfield thickness (CST)Time frame: Week 4, 8, 12, 18, 24, and 28
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07459829
Lead sponsor
Curacle Co., Ltd.
Responsible party
Sponsor
First posted
Mar 10, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 30, 2028 (estimated)
Last update
Oct 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CU06-1004

Start the discussion